Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. - Test2 - elhamkhani - TriplyDB

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

http://www.wikidata.org/entity/Q35504499

about

Immunobiology and immunotherapy in genitourinary malignancies Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Sunitinib in the treatment of metastatic renal cell carcinoma Immunotherapy for metastatic renal cell carcinoma.Renal cell carcinoma.Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.Novel immunotherapy in metastatic renal cell carcinoma.Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.Immunotherapy of advanced renal cell carcinoma: Current and future therapies.From the RNA world to the clinic.Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.Evolving Immunotherapy Approaches for Renal Cell Carcinoma.Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.Immune modulation by dendritic-cell-based cancer vaccines.Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.Personalized peptide vaccines and their relation to other therapies in urological cancer.Targeted therapies for renal cell carcinoma.Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design Advances on immunotherapy in genitourinary and renal cell carcinoma A new age for vaccine therapy in renal cell carcinoma.The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer.The current status of immunobased therapies for metastatic renal-cell carcinoma.Treatment of renal cell carcinoma: Current status and future directions.mRNA vaccines - a new era in vaccinology.Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.Immunotherapy: Controlled attack.Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.Therapeutic Vaccines for Genitourinary Malignancies Dendritic cells pulsed with generated tumor cell lysate from Phyllanthus amarus Schum. & Thonn. induces anti-tumor immune response

P2860

Q26738668-D37E129C-B40E-4E47-BF15-C613FC4DFD37 Q27686800-2C718571-9DB6-46A7-B0CC-043974D60D02 Q28072057-7DD992D2-47E6-41E1-A57D-3C55C5BA6323 Q30234458-403027BC-0032-4D67-B62D-91266D666F23 Q30235364-B8760A10-727F-4325-AD66-EB2CBC997F78 Q33814322-20F888CE-92D9-4C15-8C38-0B1CFC6DE8B8 Q33863074-5BFBEEE5-5717-4699-8A83-FF04A192126D Q33887689-00790C23-4987-4818-993E-DCF9A7D69F85 Q38540687-6FBB78FB-F07F-4384-914C-3D3D1B23546D Q38600417-53FA0687-A384-45C1-842D-A67A536E7B35 Q38762066-0DFB6ED5-1151-4F2A-B438-D52A691A1798 Q38783324-F615ACF7-411A-4AA2-888E-EA63101343C6 Q38799848-7B6FA849-F28C-47D8-B061-C940A86ED51A Q38833098-A77C013B-6A64-4A36-A585-061F4AD21150 Q38834167-851C234F-B1C5-45F6-9214-2B18EE49248D Q38851919-F85754F8-6383-4E42-ADBF-A05D386DCD5A Q38870929-FF64BB2B-EF1B-4088-807F-DBA090CAAFDD Q38913703-E0B51545-B8B5-49D4-9D36-E140367371EF Q39044249-3AFB0700-0924-4E4B-8F16-32A80F3C0D96 Q39147683-45111832-1DAF-4927-9E7D-AB65B436DC37 Q39296942-E6D34401-48FB-442E-B365-D7994A531649 Q39340541-0F45E461-F684-4482-AADD-47713B7E991E Q39425380-5B6BE13F-6047-4146-B52B-6D8F4D298F31 Q40151311-B8B421BD-9D01-4DE1-8D8C-D5176A12562D Q40994237-28A666E3-D09E-43A2-BDE4-F66D01FFE857 Q41687389-8EDAEF2E-FABC-45EA-AA5F-6951B8558B6C Q42857032-4B33FD69-5CF5-41A9-B68F-C67449B10A0A Q46776234-AF39384B-0F37-471A-901D-89595AD9C176 Q47097756-C1E4ADAC-0FBF-4079-B9EF-609909977A63 Q47726014-CD34D214-93E9-4426-B52E-8FE4B1FD30CC Q47736893-EA4CDA63-5532-4AE3-B12D-979868D0AE9B Q50035982-10BD7AA6-BCA0-4C7E-A070-5FDE3D1C32EB Q51508740-494FA6BD-39ED-4AE7-885C-5D6479C91FC9 Q52319542-171A0720-F5DF-49C9-A1A4-9F3B034DF262 Q52684454-33B6A9A6-58C0-453D-9CF5-41EE614F942B Q55190117-4C264863-A9DB-4FF5-9B3C-361A3C7242E6 Q55304879-241EF031-1699-4B59-AC11-4C40566F716A Q55418935-757AA2CD-7D02-468E-9DF1-BF389ABAFC70 Q58787586-380D22CC-4B04-44C0-84B6-343B6CF7D40F Q58799435-B9EC280D-0A25-4D7F-92DD-64833696B43B

P2860

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

http://www.wikidata.org/entity/Q35504499

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Survival with AGS-003, an auto ...... (RCC): Phase 2 study results.

@ast

Survival with AGS-003, an auto ...... (RCC): Phase 2 study results.

@en

type

label

Survival with AGS-003, an auto ...... (RCC): Phase 2 study results.

@ast

Survival with AGS-003, an auto ...... (RCC): Phase 2 study results.

@en

prefLabel

Survival with AGS-003, an auto ...... (RCC): Phase 2 study results.

@ast

Survival with AGS-003, an auto ...... (RCC): Phase 2 study results.

@en

P1433

Q35504499-6AB727E2-77BC-4420-9740-04E1DCCB1CD4

P1476

Q35504499-EE60BE8C-2041-4187-A8E7-47B12CADF6FB

P2093

Q35504499-1CCD7FFB-78BE-4B30-9F2A-2E5EEA4E76DA

Q35504499-20268617-E9BE-484B-BB4F-06ABE111EA14

Q35504499-23C6CF6E-E828-4C58-A033-49E1A7A2253C

Q35504499-3351542A-6626-4D37-BB22-6D446C15180C

Q35504499-428756DD-8DF1-489C-B742-E5F3EF70B68B

Q35504499-6A33C8A3-A2EF-4EA5-8A79-B3F6A6E67A5B

Q35504499-7E2B1DDA-38B8-4517-9E89-32F2CCAC35E4

Q35504499-99F1CD5E-5846-40E9-96A8-690C9DEB86FE

Q35504499-A01894FD-298D-40DB-88CC-4138538D5D90

Q35504499-B427D73E-520A-4196-8E47-A82126F9467A

P2860

Q35504499-00550FBD-A617-423A-83A1-06C723E5137B

Q35504499-01D8111E-EA12-4A36-916A-A10F289C1825

Q35504499-023F7AD2-D51E-461B-BC19-78E55504FBB3

Q35504499-035F6E79-ECD1-49F5-AC63-D5670AD6DC34

Q35504499-0CB4F90D-C411-4BDE-9CDE-05912CFE7F4A

Q35504499-1000B2C3-E049-43B7-A6FF-368804D5B5F5

Q35504499-126983E6-9710-4B9E-ABD4-5665A48C434D

Q35504499-13109C81-3BB4-47F8-8231-CA9ED1C8D88C

Q35504499-15ABC006-8F18-4C76-BC2F-1F817AFA1A0E

Q35504499-1B876921-1F71-48AC-9A75-6BDA73DDF0FD

P2888

Q35504499-5EF90E84-3C9F-4C64-9E2E-0165EC793E10

P304

Q35504499-2FCC033C-62DD-4413-8CCC-213D77768C5F

P31

Q35504499-8179ABA8-F8A0-444C-9496-44BAEE341E18

P356

Q35504499-74650679-5399-4C8E-994D-F921C00C6259

P478

Q35504499-AB1174B7-A3E3-4503-8317-C59B3AC1B76A

P577

Q35504499-8B3D1D88-985C-4E3D-9372-EF0E71CCCD31

P5875

Q35504499-0A00AD38-D402-4DE0-9983-A08C359C3424

P6179

Q35504499-F9E31D07-44C5-4761-981C-C574D9B8C8F3

P698

Q35504499-8D951B75-1B27-44B8-8360-1F8C1B747284

P921

Q35504499-A4547FBB-F519-4CAB-90A7-77D89A172CB8

P932

Q35504499-DDB5BB2B-95E8-43D4-A291-285943DC0572

P356

S40425-015-0055-3

P1433

Journal for Immunotherapy of Cancer

P1476

Survival with AGS-003, an auto ...... (RCC): Phase 2 study results.

@en

P2093

Arkadiusz Z Dudek

http://www.w3.org/2001/XMLSchema#string

Asim Amin

http://www.w3.org/2001/XMLSchema#string

Charles A Nicolette

http://www.w3.org/2001/XMLSchema#string

Douglas C Plessinger

http://www.w3.org/2001/XMLSchema#string

Irina Y Tcherepanova

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Holzbeierlein

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

Lawrence I Karsh

http://www.w3.org/2001/XMLSchema#string

Mark A DeBenedette

http://www.w3.org/2001/XMLSchema#string

Raymond S Lance

http://www.w3.org/2001/XMLSchema#string

P2860

Role of immunotherapy for renal cell cancer in 2011

Targeted therapeutic strategies for the management of renal cell carcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

P2888

s40425-015-0055-3

P304

14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-015-0055-3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275361359

http://www.w3.org/2001/XMLSchema#string

P6179

1009257871

http://www.w3.org/2001/XMLSchema#string

P698

25901286

http://www.w3.org/2001/XMLSchema#string

P921

P932

4404644

http://www.w3.org/2001/XMLSchema#string